ALLIANZ-WORLDWIDE-CARE
4.2.2015 15:35:52 CET | Business Wire | Pressemeddelelse
Allianz Worldwide Care has announced the launch of international healthcare plans for individuals and their families living in China, developed in partnership with sister company, Allianz China General Insurance Company. The healthcare plans, which have been designed specifically for expatriates and local nationals, will initially be available for those living in Shanghai, China’s largest population centre. The creation of the healthcare plans for individuals was a natural evolution for the two Allianz companies, following the successful launch of a range of corporate healthcare plans and the establishment of a dedicated health insurance support centre in the Pudong District of Shanghai in 2012.
Expatriates and local nationals based in Shanghai have a choice of three Core Plans, covering a wide range of in-patient and day-care treatments, along with other benefits such as medical evacuation, diagnostic tests and oncology treatment. The Core Plan can be supplemented by optional plans offering cover for out-patient, maternity, and health and wellbeing treatment. There are also two optional dental plans providing cover for general dental treatment, dental surgery, and orthodontics.
Michael Li, CEO of Allianz China General Insurance Company said, “Our local knowledge and contacts together with Allianz Worldwide Care’s global healthcare expertise have enabled us to provide an outstanding solution to individuals looking for international health insurance. The importance of private health insurance and access to private local and international medical facilities is widely recognised, particularly given China’s overcrowded public hospital system.”
Claude Daboul, Director of Sales, Marketing and Operations at Allianz Worldwide Care added, “Shanghai has a population of approximately 24 million and market insights indicated a growing demand for cover which gives individuals and their families access to private and international medical facilities. Our new healthcare plans, developed in partnership with Allianz China General Insurance Company, provide this. They offer direct settlement for in-patient, out-patient and dental treatment throughout China, and access to Allianz Worldwide Care’s extensive medical network outside of China. The modular design of these plans also means that clients can select the type and level of healthcare cover that’s absolutely right for them.
Daboul continued, “What is equally compelling for clients is that these healthcare plans offer generous levels of cover for pre-existing and newly diagnosed chronic conditions as well as oncology treatment.”
Further information is available at www.allianz.cn/en/products/individualhealthcare
//ends
About Allianz Worldwide Care
Allianz Worldwide Care is the international health and life insurance division of Allianz Worldwide Partners and part of the Allianz Group, which serves more than 75 million customers in over 70 countries worldwide. Allianz Worldwide Care provides insurance solutions for health, life and disability on a global scale. Our focus is on earning and maintaining client loyalty by providing a market leading product range, level of service and support. With a client base that includes many of the Fortune Global 500 companies, Allianz Worldwide Care continues to build a reputation for service excellence in international healthcare. www.allianzworldwidecare.com
About Allianz China General Insurance
Allianz China General Insurance Company Ltd. is headquartered in Guangzhou. Established in 2003 as Allianz’s first P&C branch office in China, it was officially approved by the Chinese Insurance Regulatory Commission in 2010, becoming a registered and fully authorised foreign-owned subsidiary. The company offers multiple insurance services including property, liability, marine, engineering, motor and domestic credit insurance, as well as short-term health insurance and accident insurance to our customers. The company has offices in Shanghai, Shenzhen, Dongguan, Foshan and Jiangmen. As a wholly owned subsidiary of the Allianz Group, the company is able to draw on the resources and expertise of one of the world’s leading insurers and financial services providers. www.allianz.cn/en/products/individualhealthcare
Contact:
Press contacts
Grayling PR
Rachel Sherry
rachel.sherry@grayling.com
+353
87 6622111
or
Nuala Ryan
nuala.ryan@grayling.com
+353
83 4212733
Information om Business Wire
Følg pressemeddelelser fra Business Wire
Skriv dig op her, og modtag pressemeddelelser på e-mail. Indtast din e-mail, klik på abonner, og følg instruktionerne i den udsendte e-mail.
Flere pressemeddelelser fra Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
I vores nyhedsrum kan du læse alle vores pressemeddelelser, tilgå materiale i form af billeder og dokumenter samt finde vores kontaktoplysninger.
Besøg vores nyhedsrum